Analysts following this coronavirus stock have darkened their post-pandemic outlook.
News & Analysis: Co-Diagnostics, Inc.
The company's recent struggles on the stock market continue.
Investors didn't like what they heard in the company's fourth-quarter update.
The company missed earnings expectations and hinted at slowing growth in 2021.
Its technology underpins a coronavirus test that's about to get much wider distribution.
With the latter appointment, the company's founder moves into a more advisory role.
This diagnostic specialist started off the year as a micro cap, but it roared ahead with its COVID-19 test.
This business came into 2020 as an unknown, and now it's generating so much growth it makes even high-profile IPOs look like they're standing still.
Not all of them were COVID-19 vaccine makers.
Investors in fast-moving biotechs made out like bandits.